Tilt Investment Management Holdings PBC Has $410,000 Stock Position in Stryker Co. (NYSE:SYK)

Tilt Investment Management Holdings PBC lessened its stake in Stryker Co. (NYSE:SYK) by 23.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,366 shares of the medical technology company’s stock after selling 430 shares during the quarter. Tilt Investment Management Holdings PBC’s holdings in Stryker were worth $410,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 61 shares during the period. Quarry LP acquired a new position in shares of Stryker during the first quarter worth about $27,000. Freedom Wealth Alliance LLC bought a new position in shares of Stryker during the fourth quarter worth about $26,000. HBC Financial Services PLLC acquired a new stake in Stryker in the 4th quarter valued at approximately $37,000. Finally, Bourgeon Capital Management LLC bought a new stake in Stryker in the 4th quarter valued at approximately $37,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of NYSE:SYK traded down $8.43 on Thursday, hitting $327.60. The company had a trading volume of 1,163,665 shares, compared to its average volume of 1,250,812. The stock has a 50 day moving average price of $350.57 and a 200 day moving average price of $312.03. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The stock has a market cap of $124.64 billion, a price-to-earnings ratio of 39.89, a P/E/G ratio of 2.72 and a beta of 0.89. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The business’s revenue was up 11.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.00 earnings per share. Analysts expect that Stryker Co. will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 0.98%. The ex-dividend date is Wednesday, March 27th. Stryker’s payout ratio is 38.79%.

Analyst Upgrades and Downgrades

SYK has been the subject of several research reports. Wells Fargo & Company raised their price target on shares of Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 31st. Roth Mkm lifted their price target on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and boosted their price target for the stock from $315.00 to $360.00 in a research report on Wednesday, January 31st. Royal Bank of Canada raised their price objective on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday. Finally, Citigroup upped their target price on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $340.45.

Insider Transactions at Stryker

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the sale, the director now directly owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 212,109 shares of company stock valued at $72,845,768. 5.90% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.